Principles for the rational use of national key monitoring drugs （the second batch）

BIAN Yuan; CHEN Min; DU Shan; LI Wenyuan; HAN Lizhu; YIN Qinan; CUI Xiaojiao; HUANG Xuefei; CHEN Zhujun; LEI Yang; HOU Yingying; YI Xiaoqing; WANG Yueyuan; ZHENG Xi; LIU Xinxia; LYU Ziyan; WU Yue; LI Lian; ZHENG Xingyue; WU Liuyun; YAN Junfeng; TONG Rongsheng

doi:10.6039/j.issn.1001-0408.2023.20.01

您当前的位置：

首页 >

文章列表页 >

Principles for the rational use of national key monitoring drugs （the second batch）

更新时间：2023-10-25

- Principles for the rational use of national key monitoring drugs （the second batch）
- ZHONGGUO YAOFANG Vol. 34, Issue 20, Pages: 2433-2453(2023)
- 作者机构：
  
  1.四川省医学科学院·四川省人民医院药学部，成都 610072
  2.电子科技大学附属医院药学部个体化药物治疗四川省重点实验室，成都　610054
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.20.01
  CLC： R969.3
- Published：30 October 2023，
  
  Received：30 July 2023，
  
  Revised：15 August 2023，
扫描看全文
边原,陈岷,杜姗等.第二批国家重点监控药品合理使用规范 ^Δ[J].中国药房,2023,34(20):2433-2453.

BIAN Yuan,CHEN Min,DU Shan,et al.Principles for the rational use of national key monitoring drugs （the second batch）[J].ZHONGGUO YAOFANG,2023,34(20):2433-2453.
边原,陈岷,杜姗等.第二批国家重点监控药品合理使用规范 ^Δ[J].中国药房,2023,34(20):2433-2453. DOI： 10.6039/j.issn.1001-0408.2023.20.01.

BIAN Yuan,CHEN Min,DU Shan,et al.Principles for the rational use of national key monitoring drugs （the second batch）[J].ZHONGGUO YAOFANG,2023,34(20):2433-2453. DOI： 10.6039/j.issn.1001-0408.2023.20.01.

摘要

为加强医疗机构药品使用监管，根据国家卫生健康委发布的《第二批国家重点监控合理用药药品目录》（简称“《目录》”），四川省医学科学院·四川省人民医院牵头与多个医疗单位的多位专家共同编写了《第二批国家重点监控药品合理使用规范》。编写组依据《世界卫生组织指南制定手册》方法，通过大量阅读和总结相关药物的国内外文献证据，采用改良德尔菲法统一专家意见，并应用推荐分级的评价、制定与评估（GRADE）方法对形成的证据进行证据质量评价，重点对《目录》中30余种药物的超说明书适应证的评估、合理用药要点和药学监护要点进行了概括，旨在推进临床用药的科学规范和有效管理，进一步提高医疗服务质量，降低不良药物反应和药物滥用的风险，促进合理用药，改善公众健康。

Abstract

In order to strengthen the supervision of the use of drugs in hospitals，the Sichuan Academy of Medical Sciences·Sichuan Provincial People’s Hospital took the lead in compiling the

Principles for the Rational Use of National Key Monitoring Drugs

（

the Second Batch

） with a number of experts from multiple medical units in accordance with the

Second Batch of National Key Monitoring Rational Drug Use List

（hereinafter referred to as “

the List

”） issued by the National Health Commission. According to the method of the

WHO Guidelines Development Manual

， the writing team used the Delphi method to unify expert opinions by reading and summarizing the domestic and foreign literature evidence of related drugs， and applied the evaluation， formulation and evaluation method of recommendation grading （GRADE） to evaluate the quality of evidence formed， focusing on more than 30 drugs in

the List

about the evaluation of off-label indications of drugs， key points of rational drug use and key points of pharmaceutical monitoring. It aims to promote the scientific standardization and effective management of clinical medication， further improve the quality of medical services， reduce the risk of adverse drug reactions and drug abuse， promote rational drug use， and improve public health.

关键词

重点监控药品合理用药规范医疗机构

Keywords

rational drug useguidelinesmedical institutions

references

国家卫生健康委员会. 质子泵抑制剂临床应用指导原则：2020年版[EB/OL].（2020-12-03）[2023-04-05]. http：//www.nhc.gov.cn/yzygj/s7659/202012/9aac2b191c844082-aac2df73b820948f.shtmlhttp://www.nhc.gov.cn/yzygj/s7659/202012/9aac2b191c844082-aac2df73b820948f.shtml.

National Health Commission of China. Guidelines for clinical application of proton pump inhibitors：2020 edition[EB/OL].（2020-12-03）[2023-04-05]. http：//www.nhc.gov.cn/yzygj/s7659/202012/9aac2b191c844082aac2df73b820948f.shtmlhttp://www.nhc.gov.cn/yzygj/s7659/202012/9aac2b191c844082aac2df73b820948f.shtml.

中国药学会医院药学专业委员会，中华医学会临床药学分会，《质子泵抑制剂优化应用专家共识》写作组. 质子泵抑制剂优化应用专家共识[J]. 中国医院药学杂志，2020，40（21）：2195-2213.

Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association，Chinese Society of Clinical Pharmacy，Writing Group of Expert Consensus on Optimal Application of Proton Pump Inhibitors. Expert consensus on optimal application of proton pump inhibitors[J]. Chin J Hosp Pharm，2020，40（21）：2195-2213.

中华医学会消化病学分会. 中国慢性胃炎共识意见：2017年，上海[J]. 中华消化杂志，2017，37（11）：721-738.

Gastroenterology Branch of Chinese Medical Association. Consensus opinion on chronic gastritis in China：Shanghai，2017[J]. Chin J Dig，2017，37（11）：721-738.

PINTO-SANCHEZ M I，YUAN Y H，HASSAN A，et al. Proton pump inhibitors for functional dyspepsia[J]. Cochrane Database Syst Rev，2017，11（11）：CD011194.

MOAYYEDI P，LACY B E，ANDREWS C N，et al. ACG and CAG clinical guideline：management of dyspepsia[J]. Am J Gastroenterol，2017，112（7）：988-1013.

VELDHUYZEN VAN ZANTEN S J，CHIBA N，ARMSTRONG D，et al. A randomized trial comparing omeprazole，ranitidine，cisapride，or placebo in Helicobacter pylori negative，primary care patients with dyspepsia：the CADET-HN study[J]. Am J Gastroenterol，2005，100（7）：1477-1488.

中华耳鼻咽喉头颈外科杂志编辑委员会咽喉组，中华医学会耳鼻咽喉头颈外科学分会咽喉学组，中华医学会耳鼻咽喉头颈外科学分会嗓音学组. 咽喉反流性疾病诊断与治疗专家共识：2022年，修订版[J]. 中华耳鼻咽喉头颈外科杂志，2022，57（10）：1149-1172.

Throat Group of the Editorial Board of Chinese Journal of Otorhinolaryngology Head and Neck Surgery，Pharyngology Group of Otorhinolaryngology Head and Neck Surgery Branch of Chinese Medical Association，Phynology Group of Otorhinolaryngology Head and Neck Surgery Branch of Chinese Medical Association. Experts consensus on diagnosis and treatment of laryngopharyngeal reflux disease：2022， revision[J]. Chin J Otorhinolaryngol Head Neck Surg，2022，57（10）：1149-1172.

KAHRILAS P J，SHAHEEN N J，VAEZI M F，et al. American Gastroenterological Association medical position statement on the management of gastroesophageal reflux disease[J]. Gastroenterology，2008，135（4）：1383-1391.

WEI C H. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux[J]. Eur Arch Otorhinolaryngol，2016，273（11）：3795-3801.

GUO H Y，MA H J，WANG J L. Proton pump inhibitor therapy for the treatment of laryngopharyngeal reflux：a meta-analysis of randomized controlled trials[J]. J Clin Gastroenterol，2016，50（4）：295-300.

QADEER M A，PHILLIPS C O，LOPEZ A R，et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis：a meta-analysis of randomized controlled trials[J]. Am J Gastroenterol，2006，101（11）：2646-2654.

EL-SERAG H B，LEE P，BUCHNER A，et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis：a placebo-controlled trial[J]. Am J Gastroenterol，2001，96（4）：979-983.

LEE Y C，LEE J S，KIM S W，et al. Influence of age on treatment with proton pump inhibitors in patients with laryngopharyngeal reflux disease：a prospective multicenter study[J]. JAMA Otolaryngol Head Neck Surg，2013，139（12）：1291-1295.

LAM P K，NG M L，CHEUNG T K，et al. Rabeprazole is effective in treating laryngopharyngeal reflux in a rando-mized placebo-controlled trial[J]. Clin Gastroenterol Hepatol，2010，8（9）：770-776.

REICHEL O，DRESSEL H，WIEDERÄNDERS K，et al. Double-blind，placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux[J]. Otolaryngol Head Neck Surg，2008，139（3）：414-420.

JONES N L，KOLETZKO S，GOODMAN K，et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents：update 2016[J]. J Pediatr Gastroenterol Nutr，2017，64（6）：991-1003.

HUANG J，ZHOU L，GENG L，et al. Randomised controlled trial：sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children：a multicentre，open-labelled study[J]. Aliment Pharmacol Ther，2013，38（10）：1230-1235.

陈玲玲. 埃索美拉唑为主的三联疗法治疗Hp阳性儿童消化性溃疡临床疗效及安全性分析[J]. 中国社区医师，2018，34（3）：22-23.

CHEN L L. Analysis of the clinical efficacy and safety of esomeprazole based triple therapy in the treatment of peptic ulcer in children with Hp positive[J]. Chin Community Dr，2018，34（3）：22-23.

KOTILEA K，CADRANEL S，SALAME A，et al. Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children[J]. Helicobacter，2021，26（4）：e12825.

WARD R M，KEARNS G L，TAMMARA B，et al. A multicenter，randomized，open-label，pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease[J]. J Clin Pharmacol，2011，51（6）：876-887.

HADDAD I，KIERKUS J，TRON E，et al. Efficacy and safety of rabeprazole in children（1-11 years） with gastroesophageal reflux disease[J]. J Pediatr Gastroenterol Nutr，2013，57（6）：798-807.

HADDAD I，KIERKUS J，TRON E，et al. Maintenance of efficacy and safety of rabeprazole in children with endoscopically proven GERD[J]. J Pediatr Gastroenterol Nutr，2014，58（4）：510-517.

GILGER M A，TOLIA V，VANDENPLAS Y，et al. Safety and tolerability of esomeprazole in children with gastroesophageal reflux disease[J]. J Pediatr Gastroenterol Nutr，2015，60（Suppl 1）：S16-S23.

TOLIA V，YOUSSEF N N，GILGER M A，et al. Esomeprazole for the treatment of erosive esophagitis in children：an international，multicenter，randomized，parallel-group，double-blind（for dose）study[J]. J Pediatr Gastroenterol Nutr，2015，60（Suppl 1）：S24-S30.

WINTER H，GUNASEKARAN T，TOLIA V，et al. Esomeprazole for the treatment of GERD in infants ages 1-11 months[J]. J Pediatr Gastroenterol Nutr，2015，60（Suppl 1）：S9-S15.

ROSEN R，VANDENPLAS Y，SINGENDONK M，et al. Pediatric gastroesophageal reflux clinical practice guidelines：joint recommendations of the North American Society for Pediatric Gastroenterology，Hepatology，and Nutrition and the European Society for Pediatric Gastroenterology，Hepatology，and Nutrition[J]. J Pediatr Gastroenterol Nutr，2018，66（3）：516-554.

王刚，李在玲，谢晓丽，等. 儿童质子泵抑制剂合理使用专家共识：2019年版[J]. 中国实用儿科杂志，2019，34（12）：977-981.

WANG G，LI Z L，XIE X L，et al. Expert consensus on the proper application of proton pump inhibitors in children：2019 edition[J]. Chin J Pract Pediatr，2019，34（12）：977-981.

TAMMARA B K，SULLIVAN J E，ADCOCK K G，et al. Randomized，open-label，multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through ＜6 years with gastro-oesophageal reflux disease[J]. Clin Pharmacokinet，2011，50（8）：541-550.

中华医学会儿科学分会消化学组，中国中药协会儿童健康与药物研究专业委员会消化学组，中华儿科杂志编辑委员会. 中国儿童功能性消化不良诊断和治疗共识：2022版[J]. 中华儿科杂志，2022，60（8）：751-755.

The Group of Gastroenterology，the Society of Pediatrics，Chinese Medical Association，the Group of Gastroentero-logy，China Association of Traditional Chinese Medicine Children’s Health and Drug Research Professional Committee，the Editorial Board of Chinese Journal of Pediatrics，et al. Expert consensus on diagnosis and treatment of functional dyspepsia in Chinese children：2022[J]. Chin J Pediatr，2022，60（8）：751-755.

BROWNE P D，NAGELKERKE S C J，VAN ETTEN-JAMALUDIN F S，et al. Pharmacological treatments for functional nausea and functional dyspepsia in children：a systematic review[J]. Expert Rev Clin Pharmacol，2018，11（12）：1195-1208.

DEHGHANI S M，IMANIEH M H，OBOODI R，et al. The comparative study of the effectiveness of cimetidine，ranitidine，famotidine，and omeprazole in treatment of children with dyspepsia[J]. ISRN Pediatr，2011，2011：219287.

潘伟思. 奥美拉唑与西咪替丁静脉注射治疗儿童上消化道出血比较[J]. 中国新药与临床杂志，2001，20（4）：318-319.

PAN W S. Comparison of omeprazole and cimetidine intravenous injection in the treatment of upper gastrointestinal bleeding in children[J]. Chin J N Drugs Clin Reme-dies，2001，20（4）：318-319.

VAN RENSBURG C，BERGHÖFER P，ENNS R，et al. Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia[J]. Curr Med Res Opin，2008，24（7）：2009-2018.

IWAKIRI R，TOMINAGA K，FURUTA K，et al. Randomised clinical trial：rabeprazole improves symptoms in patients with functional dyspepsia in Japan[J]. Aliment Pharmacol Ther，2013，38（7）：729-740.

SONDAK V K，WONG S L，GERSHENWALD J E，et al. Evidence-based clinical practice guidelines on the use of sentinel lymph node biopsy in melanoma[J/OL]. Am Soc Clin Oncol Educ Book，2013[2023-05-11]. https：//pubmed.ncbi.nlm.nih.gov/23714536/.DOI：10.14694/EdBook_AM. 2013.33.e320https://pubmed.ncbi.nlm.nih.gov/23714536/.DOI:10.14694/EdBook_AM.2013.33.e320.

MAJEWSKI M，SAROSIEK I，COOPER C J，et al. Ga-stric pH and therapeutic responses to exsomeprazole in patients with functional dyspepsia： potential clinical implications[J]. Am J Med Sci，2016，352（6）：582-592.

KAMIYA T，SHIKANO M，KUBOTA E，et al. A multicenter randomized trial comparing rabeprazole and itopride in patients with functional dyspepsia in Japan：the NAGOYA study[J]. J Clin Biochem Nutr，2017，60（2）：130-135.

YANG J C，LIN C J，WANG H L，et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection[J]. Clin Gastroenterol Hepatol，2015，13（5）：895-905.

ZENG Y，YE Y T，LIANG D S，et al. Meta-analysis of the efficacy of lansoprazole and omeprazole for the treatment of H. pylori-associated duodenal ulcer[J]. Int J Physiol Pathophysiol Pharmacol，2015，7（3）：158-164.

YANG J，ZHANG Y，FAN L，et al. Eradication efficacy of modified dual therapy compared with bismuth-containing quadruple therapy as a first-line treatment of Helicobacter pylori[J]. Am J Gastroenterol，2019，114（3）：437-445.

HWONG-RUEY LEOW A，CHANG J V，GOH K L. Searching for an optimal therapy for H. pylori eradication：high-dose proton-pump inhibitor dual therapy with amoxicillin vs. standard triple therapy for 14 days[J]. Helicobacter，2020，25（5）：e12723.

XU H M，WANG W C，MA X N，et al. Comparative efficacy and safety of high-dose dual therapy，bismuth-based quadruple therapy and non-bismuth quadruple therapies for Helicobacter pylori infection：a network meta-analysis[J]. Eur J Gastroenterol Hepatol，2021，33（6）：775-786.

中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 中华消化杂志，2022，42（11）：745-756.

Helicobacter pylori Study Group，Society of Gastroentero-logy，Chinese Medical Association. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment[J]. Chin J Dig，2022，42（11）：745-756.

BABIKER MOHAMED M A，ABDELWAHAB ABDELKARIM W A，SALIH AABDEEN M A，et al. Evidence-based clinical practice guidelines for the ma-nagement of perioperative hypothermia：systematic review，critical appraisal，and quality assessment with the AGREE Ⅱ instrument[J]. Ann Med Surg，2022，79：103887.

GUAN J L，HU Y L，AN P，et al. Comparison of high-dose dual therapy with bismuth-containing quadruple therapy in Helicobacter pylori-infected treatment-naive patients：an open-label，multicenter，randomized controlled trial[J]. Pharmacotherapy，2022，42（3）：224-232.

HAN Y Y，LONG H，LIN Y，et al. Optimized dual therapy for treatment-naive patients of Helicobacter pylori infection：a large-scale prospective，multicenter，open-label，randomized controlled study[J]. Helicobacter，2022，27（5）：e12922.

SHAO Q Q，YU X C，YU M，et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China：a single-center，prospective，open-label，randomized-controlled trial[J]. Helicobacter，2022，27（2）：e12876.

ANZIĆ S A，TURKALJ M，ŽUPAN A，et al. Eight weeks of omeprazole 20 mg significantly reduces both laryngopharyngeal reflux and comorbid chronic rhinosinusitis signs and symptoms： randomised，double-blind，placebo-controlled trial[J]. Clin Otolaryngol，2018，43（2）：496-501.

CHENG A C. Melioidosis：advances in diagnosis and treatment[J]. Curr Opin Infect Dis，2010，23（6）：554-559.

SANFORD A P. 热病：桑福德抗微生物治疗指南[M]. 50版.北京：中国协和医科大学出版社，2021：73.

SANFORD A P. Fever：Sanford antibiotic treatment guidelines[M]. 50 edition. Beijing：Peking Union Medical College Press，2021：73.

中国微生物学会医学微生物学与免疫学专业委员会，重庆市微生物学会临床微生物专业委员会，毛旭虎，等. 类鼻疽诊断与治疗专家共识[J]. 中华传染病杂志，2022，40（10）：577-583.

Medical Microbiology and Immunology Committee of Chinese Society for Microbiology，Clinical Microbiology Committee of Chongqing Society for Microbiology，MAO X H，et al. Expert consensus on diagnosis and treatment of melioidosis[J]. Chin J Infect Dis，2022，40（10）：577-583.

PAUL M，SHANI V，MUCHTAR E，et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis[J]. Antimicrob Agents Chemother，2010，54（11）：4851-4863.

中国老年医学学会，国家老年疾病临床医学研究中心，解放军老年医学专业委员会. 感染诱发的老年多器官功能障碍综合征诊断与治疗中国指南2019[J]. 中华老年多器官疾病杂志，2019，18（11）：801-838.

Chinese Geriatrics Society，National Clinical Research Center for Geriatric Diseases，Chinese PLA Geriatric Committee. 2019 China guideline for diagnosis and treatment of infection-induced multiple organ dysfunction syndrome in the elderly[J]. Chin J Mult Organ Dis Elder，2019，18（11）：801-838.

SHANE A L，MODY R K，CRUMP J A，et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea[J]. Clin Infect Dis，2017，65（12）：1963-1973.

MCDONALD L C，GERDING D N，JOHNSON S，et al. Clinical practice guidelines for clostridium difficile infection in adults and children：2017 update by the Infectious Diseases Society of America（IDSA）and Society for Healthcare Epidemiology of America（SHEA）[J]. Clin Infect Dis，2018，66（7）：987-994.

WHO. WHO consolidated guidelines on tuberculosis. Module 4：treatment-drug-resistant tuberculosis treatment，2022 update[EB/OL].（2022-12-15）[2023-04-05].https：//www.who.int/publications/i/item/9789240063129https://www.who.int/publications/i/item/9789240063129.

NUNN A J，PHILLIPS P P J，MEREDITH S K，et al. A trial of a shorter regimen for rifampin-resistant tuberculosis[J]. N Engl J Med，2019，380（13）：1201-1213.

GAFTER-GVILI A，FRASER A，PAUL M，et al. Meta-analysis：antibiotic prophylaxis reduces mortality in neutropenic patients[J]. Ann Intern Med，2005，142（12 Pt 1）：979-995.

KLASTERSKY J，NAUROIS J D，ROLSTON K，et al. Management of febrile neutropaenia：ESMO clinical practice guidelines[J]. Ann Oncol，2016，27（Suppl 5）：v111-v118.

KAHRAMANOĞLU AKSOY E， PIRINÇCI SAPMAZ F， GÖKTAŞ Z，et al. Comparison of Helicobacter pylori eradication rates of 2-week levofloxacin-containing triple therapy，levofloxacin-containing bismuth quadruple therapy，and standard bismuth quadruple therapy as a first-line regimen[J]. Med Princ Pract，2017，26（6）：523-529.

DAVIES L，ANGUS R M，CALVERLEY P M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease：a prospective randomised controlled trial[J]. Lancet，1999，354（9177）：456-460.

NIEWOEHNER D E，ERBLAND M L，DEUPREE R H，et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group[J]. N Engl J Med，1999，340（25）：1941-1947.

DING Z，LI X，LU Y，et al. A randomized，controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease[J]. Respir Med，2016，121：39-47.

SIVAPALAN P，INGEBRIGTSEN T S，RASMUSSEN D B，et al. COPD exacerbations：the impact of long versus short courses of oral corticosteroids on mortality and pneumonia：nationwide data on 67 000 patients with COPD followed for 12 months[J]. BMJ Open Respir Res，2019，6（1）：e000407.

中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南：2021年修订版[J]. 中华结核和呼吸杂志，2021，44（3）：170-205.

Chronic Obstructive Pulmonary Disease Group of Chinese Thoracic Society，Chronic Obstructive Pulmonary Disease Committee of Chinese Association of Chest Physician. Guidelines for the diagnosis and management of chronic obstructive pulmonary disease：revised version 2021[J]. Chin J Tuberc Respir Dis，2021，44（3）：170-205.

RAMAKRISHNAN S，JrNICOLAU D V，LANGFORD B，et al. Inhaled budesonide in the treatment of early COVID-19（STOIC）：a phase 2，open-label，randomised controlled trial[J]. Lancet Respir Med，2021，9（7）：763-772.

REIS G，DOS SANTOS MOREIRA SILVA E A，MEDEIROS SILVA D C，et al. Oral fluvoxamine with inhaled budesonide for treatment of early-onset COVID-19：a randomized platform trial[J]. Ann Intern Med，2023，176（5）：667-675.

国家卫生健康委员会办公厅，国家中医药管理局综合司. 关于印发新型冠状病毒感染诊疗方案（试行第十版）的通知[EB/OL].（2023-01-05）[2023-04-05].http：//www.nhc.gov.cn/ylyjs/pqt/2023-01/32de5b2ff9bf4eaa88e75bdf7223a65a.shtmlhttp://www.nhc.gov.cn/ylyjs/pqt/2023-01/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml.

General Office of the National Health Commission of China，General Department of National Adiministration of Traditional Chinese Medicine. Diagnosis and treatment plan for novel coronavirus infection：10th edition on trial[EB/OL]. （2023-01-05）[2023-04-05]. http：//www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtmlhttp://www.nhc.gov.cn/ylyjs/pqt/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml.

YU L M，BAFADHEL M，DORWARD J，et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK（PRINCIPLE）：a randomised，controlled，open-label，adaptive platform trial[J]. Lancet，2021，398（10303）：843-855.

CAI C，HE M Z，ZHONG S Q，et al. Add-on montelukast vs double-dose budesonide in nonasthmatic eosinophilic bronchitis：a pilot study[J]. Respir Med，2012，106（10）：1369-1375.

BAO W P，LIU P，QIU Z M，et al. Efficacy of add-on montelukast in nonasthmatic eosinophilic bronchitis：the additive effect on airway inflammation，cough and life quality[J]. Chin Med J，2015，128（1）：39-45.

CÔTÉ A，RUSSELL R J，BOULET L P，et al. Managing chronic cough due to asthma and NAEB in adults and adolescents：CHEST guideline and expert panel report[J]. Chest，2020，158（1）：68-96.

TAPIAINEN T，AITTONIEMI J，IMMONEN J，et al. Finnish guidelines for the treatment of laryngitis，whee-zing bronchitis and bronchiolitis in children[J]. Acta Pae-diatr，2016，105（1）：44-49.

许政敏，王智楠，姚红兵. 儿童急性感染性鼻-鼻窦炎诊疗：临床实践指南：2014年制订[J]. 中国实用儿科杂志，2015，30（7）：512-514.

XU Z M，WANG Z N，YAO H B. Diagnosis and treatment of acute infectious rhinosinusitis in children：clinical practice guidelines：formulated in 2014[J]. Chin J Pract Pe-diatr，2015，30（7）：512-514.

隗强，邵换璋，常薇，等. 机械通气雾化吸入治疗临床路径[J]. 中华危重病急救医学，2020，32（12）：1409-1413.

KUI Q，SHAO H Z，CHANG W，et al. Clinical path of mechanical ventilation and atomization inhalation therapy[J]. Chin Crit Care Med，2020，32（12）：1409-1413.

GAO S G，BARELLO S，CHEN L，et al. Clinical guidelines on perioperative management strategies for enhanced recovery after lung surgery[J]. Transl Lung Cancer Res，2019，8（6）：1174-1187.

缺血性肠病诊治中国专家建议写作组，中华医学会老年医学分会，《中华老年医学杂志》编辑委员会. 老年人缺血性肠病诊治中国专家建议：2011[J]. 中华老年医学杂志，2011，30（1）：1-6.

Chinese Expert Advice Writing Group for the Diagnosis and Treatment of Ischemic Bowel Disease，Geriatrics Branch of Chinese Medical Association，Editorial Board of Chinese Journal of Geriatrics. Chinese experts for diagnosis and treatment of ischemic enteropathy：2011[J]. Chin J Geriatr，2011，30（1）：1-6.

中国医师协会急诊医师分会，解放军急救医学专业委员会，中华医学会急诊医学分会，等. 2020年中国急性肠系膜缺血诊断与治疗专家共识[J]. 中华急诊医学杂志，2020（10）：1273-1281.

Emergency Physician Branch of Chinese Medical Doctor Association，Emergency Medicine Professional Committee of PLA，Emergency Medicine Branch of Chinese Medical Association，et al. Expert consensus on diagnosis and treatment of acute mesenteric ischemia in China， 2020[J]. Chin J Emerg Med，2020，29（10）：1273-1281.

Aurobindo. Cefpodoxime proxetil：cefpodoxime proxetil tablet，film coated[EB/OL]. [2023-04-05]. https：//www.drugfuture.com/fda-ndc/label.aspxhttps://www.drugfuture.com/fda-ndc/label.aspx.

ROBERTSON L，ANDRAS A. Prostanoids for intermittent claudication[J]. Cochrane Database Syst Rev，2013（4）：CD000986.

中国医疗保健国际交流促进会糖尿病足病分会，国际血管联盟中国分部糖尿病足病专家委员会. 中国糖尿病足诊治指南[J]. 中国临床医生杂志，2020，48（1）：19-27.

Diabetic Podiatry Branch of Chinese Association for the Promotion of International Exchange in Healthcare， Expert Committee on Diabetic Foot Disease， China Branch of International Vascular Alliance. Guidelines for diagnosis and treatment of diabetic foot in China[J]. Chin J Clin，2020，48（1）：19-27.

HWANG E S，SONG S B. Possible adverse effects of high-dose nicotinamide：mechanisms and safety assessment[J]. Biomolecules，2020，10（5）：687.

FDA. FDA label-kedbumin：albumin（human）injection， solution[EB/OL]. [2023-04-05]. https：//www.fda.gov/media/80280/downloadhttps://www.fda.gov/media/80280/download.

冯明丽，王晓春，杨长青. 大量放腹水后输注人体白蛋白疗效的Meta分析[J]. 肝脏，2015，20（5）：381-386.

FENG M L，WANG X C，YANG C Q. A meta-analysis of albumin infusion in patients undergoing large-volume paracentesis[J]. Chin Hepatol，2015，20（5）：381-386.

李慧博，门鹏，王宇，等. 《人血白蛋白用于肝硬化治疗的快速建议指南》解读[J]. 临床药物治疗杂志，2018，16（12）：10-16.

LI H B，MEN P，WANG Y，et al. Expert consensus on Rapid Advice Guidelines for the Pharmacological Mana-gement of Human Albumin in Patients with Liver Cirrhosis[J]. Clin Med J，2018，16（12）：10-16.

SALERNO F，NAVICKIS R J，WILKES M M. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis：a meta-analysis of randomized trials[J]. Clin Gastroenterol Hepatol，2013，11（2）：123-130.

TSIPOTIS E，SHUJA A，JABER B L. Albumin dialysis for liver failure：a systematic review[J]. Adv Chronic Kidney Dis，2015，22（5）：382-390.

KATO M，WATANABE M，KONISHI S，et al. Rando-mized，double-blind，placebo-controlled crossover trial of famotidine in patients with functional dyspepsia[J]. Aliment Pharmacol Ther，2005，21（Suppl 2）：27-31.

柯美云. 中国消化不良的诊治指南：2007，大连[J]. 中华消化杂志，2007，27（12）：832-834.

KE M Y. Guidelines for diagnosis and treatment of dyspepsia in China：Dalian，2007[J]. Chin J Dig，2007，27（12）：832-834.

MIWA H，NAGAHARA A，ASAKAWA A，et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021[J]. J Gastroenterol，2022，57（2）：47-61.

KINOSHITA Y，CHIBA T，FUTURE Study Group. Therapeutic effects of famotidine on chronic symptomatic gastritis：subgroup analysis from FUTURE study[J]. J Gastroenterol，2012，47（4）：377-386.

Views

112

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Review and comment rules of national key monitoring drug prescriptions （medical orders）

Guideline for the prevention and control of occupational exposure risks to cytotoxic drugs in medical institutions

2008－2012年江苏省医疗机构制剂的现状分析

Related Author

BIAN Yuan

CHEN Min

DU Shan

LI Wenyuan

HAN Lizhu

YIN Qinan

CUI Xiaojiao

HUANG Xuefei

Related Institution

School of Medicine， University of Electronic Science and Technology of China

Personalized Drug Therapy Key Laboratory of Sichuan Provincial，Dept. of Pharmacy，Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital/ Affiliated Hospital of UESTC

Sichuan Provincial Key Laboratory of Personalized Drug Therapy， the Affiliated Hospital of UESTC

Personalized Drug Therapy Key Laboratory of Sichuan Provincial， Dept. of Pharmacy， Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital/Affiliated Hospital of UESTC

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰